Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2021 | 03-2020 | 03-2019 | 03-2018 | 03-2017 | |
| Sales | 30,059,430 | 30,278,930 | 18,875,020 | 15,934,780 | 16,108,070 |
| Cost of Goods | -9,346,495 | 10,025,830 | 5,937,210 | 4,463,289 | 5,196,421 |
| Gross Profit | 39,405,930 | 20,253,100 | 12,937,810 | 11,471,490 | 10,911,650 |
| Operating Expenses | 15,925,314 | 19,330,180 | 11,093,290 | 9,295,680 | 9,462,510 |
| Operating Income | 4,787,128 | 923,754 | 1,844,721 | 2,176,101 | 1,449,563 |
| Interest Expense | 2,337,131 | 1,518,055 | 749,601 | 287,352 | 216,225 |
| Other Income | 992,612 | 35,365 | -241,056 | 66,096 | 99,780 |
| Pre-tax Income | 3,442,609 | -558,937 | 854,064 | 1,954,845 | 1,333,118 |
| Income Tax | -93,398 | -966,405 | -127,062 | 274,473 | 258,847 |
| Net Income Continuous | 3,536,007 | 407,468 | 981,126 | 1,680,372 | 1,074,271 |
| Minority Interests | 1,560 | 451 | -1,008 | -1,602 | 5,329 |
| Net Income | $3,534,447 | $407,017 | $982,134 | $1,681,974 | $1,068,942 |
| EPS Basic Total Ops | 1.13 | 0.13 | 0.51 | 1.08 | 0.68 |
| EPS Basic Continuous Ops | 1.13 | 0.13 | 0.51 | 1.08 | 0.69 |
| EPS Diluted Total Ops | 1.12 | 0.13 | 0.51 | 1.07 | 0.68 |
| EPS Diluted Continuous Ops | 1.12 | 0.13 | 0.51 | 1.07 | 0.68 |
| EPS Diluted Before Non-Recurring Items | 1.98 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $28,741,030 | $6,293,325 | $4,296,734 | $3,815,245 | $3,521,483 |